This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

Trial Details

NCT ID
NCT06451497
Phase
PHASE1
Sponsor
Zumutor Biologics Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ZM008
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Austin, TX 78758, Texas, United States|30.26715,-97.74306
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Adult patients aged 18 years and older, at the time of signing the informed consent form.
  • Part 1: Patients with histologically confirmed diagnosis of advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic sol…
  • Patients with tumors with actionable mutations should have progressed to all approved targeted therapies or have them contraindicated.
  • The patient has measurable disease with RECIST 1. 1 on computed tomography (CT), positron emission tomography (PET)/CT, or magnetic resonance imagi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →